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Abstract
Molecular diagnostics of autosomal dominant polycystic kidney disease (AD-
PKD) relies on mutation screening of PKD1 and PKD2, which is complicated
by extensive allelic heterogeneity and the presence of six highly homologous
sequences of PKD1. To date, specific sequencing of PKD1 requires laborious
long-range amplifications. The high cost and long turnaround time of PKD1
and PKD2 mutation analysis using conventional techniques limits its wide-
spread application in clinical settings. We performed targeted next-generation
sequencing (NGS) of PKD1 and PKD2. Pooled barcoded DNA patient libraries
were enriched by in-solution hybridization with PKD1 and PKD2 capture
probes. Bioinformatics analysis was performed using an in-house developed
pipeline. We validated the assay in a cohort of 36 patients with previously
known PKD1 and PKD2 mutations and five control individuals. Then, we used
the same assay and bioinformatics analysis in a discovery cohort of 12 unchar-
acterized patients. We detected 35 out of 36 known definitely, highly likely, and
likely pathogenic mutations in the validation cohort, including two large dele-
tions. In the discovery cohort, we detected 11 different pathogenic mutations in
10 out of 12 patients. This study demonstrates that laborious long-range PCRs
of the repeated PKD1 region can be avoided by in-solution enrichment of
PKD1 and PKD2 and NGS. This strategy significantly reduces the cost and time
for simultaneous PKD1 and PKD2 sequence analysis, facilitating routine genetic
diagnostics of ADPKD.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD;
OMIM IDs: 173900; 613095) is the most common inher-
ited kidney disease, with an incidence of 1 in 400–1000
(Iglesias et al. 1983; Dalgaard and Norby 1989). ADPKD
is caused by mutations in PKD1 (16p13.3; OMIM ID:
601313) in approximately 85% of the cases (The Euro-
pean Polycystic Kidney Disease Consortium 1994), and in
PKD2 (4q21; OMIM ID: 173910) in the remaining 15%
(Mochizuki et al. 1996). ADPKD is characterized by the
development and progressive enlargement of cysts in the
kidneys and other organs, eventually leading to end-stage
renal disease (ESRD). The ADPKD phenotype displays a
significant variability that is greatly influenced by the
affected gene. Thus, PKD1 patients have a median age at
ESRD of 58 years compared to 79 years for PKD2
mutated patients (Cornec-Le Gall et al. 2013).
Diagnosis of ADPKD is mainly performed by renal
imaging such as ultrasonography, computed tomogra-
phy, or magnetic nuclear resonance (Pei et al. 2009).
However, molecular diagnostics is necessary in several
situations: (1) when a definite diagnosis is required in
young individuals, such as a potential living related
donor in an affected family with equivocal imaging
data; (2) in patients with a negative family history of
ADPKD, because of potential phenotypic overlap with
several other kidney cystic diseases; (3) in families
affected by early-onset polycystic kidney disease, since
in this cases hypomorphic alleles and/or oligogenic
inheritance can be involved (Rossetti et al. 2009; Berg-
mann et al. 2011; Harris and Hopp 2013); and (4) in
patients requesting genetic counseling, especially in
couples wishing a preimplantation genetic diagnosis
(Harris and Rossetti 2010).
Approximately 70% of the 50 genomic region of the
PKD1 gene (exons 1–33) is duplicated six times on chro-
mosome 16p within six pseudogenes (PKD1P1 to
PKD1P6), which share a 97.7% sequence identity with the
genuine gene (Bogdanova et al. 2001; Rossetti et al. 2012).
This, together with a high GC content, the presence of
many missense variants, the absence of mutation hot spots,
and the high allelic heterogeneity of ADPKD, makes the
molecular diagnostics of ADPKD challenging. In addition,
most mutations are private variants, with a total of 1272
pathogenic PKD1 and 202 pathogenic PKD2 mutations
reported to date (March 2014, ADPKD Database [PKDB],
http://pkdb.mayo.edu). Thus, genetic diagnosis by conven-
tional techniques of a new ADPKD family requires long-
range polymerase chain reaction (LR-PCR) of the repeated
region of PKD1 followed by nested PCRs (Rossetti et al.
2002), combined with Sanger sequencing of all 46 PKD1
and 15 PKD2 exons. When pathogenic mutations are not
identified by Sanger sequencing, multiplex ligation-
dependent probe amplification (MLPA) analysis is also
performed to identify potential insertions and deletions.
Therefore, there is a demand for more simple and cost-
effective molecular approaches that could be used for
routine diagnosis, especially now with the coming specific
therapies that will require differential genetic diagnosis
(Torres and Harris 2006). To address these challenges, we
have developed and validated an assay that couples gen-
ome partitioning and next-generation sequencing (NGS),
to comprehensively perform in one-step mutation screen-
ing in PKD1 and PKD2, as an alternative to cumbersome
conventional genetic testing methods.
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Material and Methods
Subjects
High-quality genomic DNA from 53 unrelated patients
was obtained from blood lymphocytes, using standard
protocols. The validation cohort included 36 ADPKD
patients and five control individuals that had previously
undergone conventional genetic diagnosis by Sanger
sequencing of all PKD1 and PKD2 exons and, if negative,
MLPA was also applied. The discovery cohort consisted
of 12 ADPKD consecutive patients received for genetic
diagnosis for which no mutations were known. ADPKD
diagnosis was based on standard clinical and imaging cri-
teria. Blood samples were obtained from other family
members if they were available. All samples were codified
and bioinformatics mutation analysis was blindly per-
formed. Signed informed consent was obtained for all
participants. This study was approved by the institutional
review board.
Capture and multiplexed sequencing of the
PKD1 and PKD2 genes
To carry out DNA capture, we designed a custom Nim-
bleGen SeqCap EZ Choice Library (Roche, Inc., Madison,
WI) to target the complete genomic sequence of the
PKD1 and PKD2 genes, and 1 kb of genomic sequence
flanking at the 50 and 30 ends of each gene, accounting
for 121,322 bp. Our design also included probes to target
additional genes related to other human inherited
diseases, for a total of 2.1 Mb of captured DNA after
removal of repetitive sequences. DNA probes were
selected using the most stringent settings for probe design
(uniqueness tested by Sequence Search and Alignment by
Hashing Algorithm [SSAHA]) (Ning et al. 2001). How-
ever, in order to be able to generate capture probes for
the duplicated PKD1 regions, we altered the settings for
probe design of this specific region to allow probes to
have up to 10 close matches in the genome. No probe
redundancy was allowed in the final capture design for
the rest of target regions. The Browser Extensible Data
file of captured regions is available on request to the
authors.
Libraries were prepared with the TruSeq DNA Sample
Preparation Kits (Illumina, Inc., San Diego, CA). Geno-
mic capture from pooled libraries was carried out using
NimbleGen SeqCap EZ Library (Roche, Inc.) following
User’s Guide v3.0 instructions, as previously described
(Trujillano et al. 2013). The libraries of the patients of
the validation cohort and the five controls were prepared
and sequenced together with seven samples of other dis-
eases using the same capture design and enrichment pro-
tocol in two pools of 24 samples, for a total of 48
samples multiplexed in two HiSeq 2000 (Illumina, Inc.)
lanes to generate 2 9 100 bp paired-end reads. The 12
patients of the discovery cohort were enriched in a single
capture reaction and were sequenced in a Miseq (Illu-
mina, Inc.) run to generate 2 9 250 bp paired-end reads.
Bioinformatics analysis and mutation
identification and classification
The resulting fastq files were analyzed with an in-house
developed pipeline previously described (Trujillano et al.
2013). All the bioinformatics tools used in this study were
run using default settings unless stated otherwise. For the
patients included in this study, only the sequencing data
produced for PKD1 and PKD2 were analyzed, as stated in
the signed informed consent. The reference sequences
used were NM_001009944.2 for PKD1 and NM_000297.2
for PKD2. In order to identify pathogenic mutations that
could cause ADPKD, we applied the following cascade of
filtering steps (Walsh et al. 2010):
1 We required all candidate variants on both sequenced
DNA strands and to account for ≥20% of total reads at
that site in order to filter out spurious variant calls caused
by misaligned reads in the duplicated region of PKD1.
2 Common polymorphisms (≥5% in the general popula-
tion) were discarded by comparison with dbSNP 137,
the 1000G, the Exome Variant Server (http://evs.gs.
washington.edu), and an in-house exome variant data-
base to filter out both common benign variants and
recurrent artifact variant calls, especially in the dupli-
cated PKD1 regions. However, since these databases
also contain known disease-associated mutations, all
detected variants were compared to gene mutation
databases (The Human Gene Mutation Database
[HGMD], www.hgmd.cf.ac.uk and ADPKD Database
[PKDB], http://pkdb.mayo.edu).
3 Mutations that could give rise to premature truncated
proteins, that is, stop mutations, exonic deletions/inser-
tions, and large genomic rearrangements were classified
as definitely pathogenic.
4 Missense and noncanonical splicing variants were con-
sidered a priori Unclassified Sequence Variants (UCV)
and their potential pathogenicity was evaluated using an
in silico scoring system developed for PKD1 and PKD2
genes as previously described (Rossetti et al. 2007). This
scoring system takes into consideration a number of in
silico predictors (Grantham 1974; Tavtigian et al. 2006;
Rossetti et al. 2007) and population data. We scored
each of these factors, the sum of which resulted in an
overall Variant Score (VS). The UCV were classified
into four groups: highly likely pathogenic (VS ≥ 11);
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likely pathogenic (5 ≤ VS ≤ 10), indeterminate
(0 ≤ VS ≤ 4), and highly likely neutral (VS ≤ 1)
(Rossetti et al. 2007).
We considered to be pathogenic mutations those sequence
variants predicted to result in a truncated protein (classi-
fied as definitely pathogenic) and those not found in
healthy controls, that segregated with the disease in
families and expected to severely alter the protein
sequence using in silico predictors (classified as highly
likely pathogenic and likely pathogenic variants).
If no pathogenic mutations were identified, the bioin-
formatics pipeline automatically reported the target
sequences that presented low or inexistent sequence cov-
erage. These regions were screened by Sanger sequencing
since they were more likely to contain the pathogenic
variants missed by our NGS approach. Validation of
newly identified single-nucleotide variants (SNVs) was
performed by Sanger sequencing.
Results
PKD1 and PKD2 enrichment
Eighty-one percent of the PKD1- and PKD2-targeted
bases could be covered with capture baits for a final tar-
geted region of 98,524 bp divided into 99 individual
regions, with lengths ranging from 65 to 6,493 bp (aver-
age of 995 bp) (Table S1). Noteworthy, 100% of all cod-
ing sequences, that is, the complete 46 and 15 exons of
PKD1 and PKD2, respectively, were covered by capture
baits. The target regions that precluded bait tilling corre-
spond only to intronic and intergenic sequences.
Sequencing statistics
In the validation cohort, an evenly distributed mean depth
of coverage of 331X and 481X for PKD1 and PKD2 was
achieved, respectively, on average across samples (Table 1).
We achieved a sequencing depth of 289X for the 46 exons
of PKD1 and 453X for the 15 exons of PKD2, on average
across samples (Table S2). Ninety-five percent of the cod-
ing base pairs of PKD1 and 94% of PKD2 were covered by
more than 20 reads, which is enough for an accurate detec-
tion of known and novel mutations. Only exons 1 and 42
of PKD1 and exon 1 of PKD2 were not captured and
sequenced at an adequate read depth (Fig. 1).
Due to the lower throughput of the MiSeq sequencer,
the average coverage achieved in the discovery cohort was
of 81X and 174X for PKD1 and PKD2, respectively, across
the 12 samples (Table 1). For a comprehensive summary
of the obtained sequencing results, see also Tables S3, S4.
Detection of PKD1 and PKD2 mutations
in the validation cohort
For the validation cohort we selected samples with as
many different types of PKD1 and PKD2 mutations as
possible, including SNVs, short insertions and deletions
(InDels), and large structural variants (SVs). We identi-
fied 35 out of 36 previously known different pathogenic
mutations (30 in PKD1 and five in PKD2) in their correct
heterozygous state (Table 2). These results would have led
to a diagnostic rate of 97.2%. Noteworthy, 25 (70%) of
these mutations were spread along different exons within
the segmentally duplicated regions of the PKD1 gene,
highlighting the robustness of our approach even for
Table 1. Average sequencing quality control and coverage statistics of PKD1 and PKD2 in the validation and discovery cohorts.
Cohort
Validation Discovery
Average SD Average SD
QC-passed reads 14452006.67 2252761.13 1303016.25 293339.48
Mapped 14328976.12 2236282.41 1002567.63 269009.02
Properly paired 14140971.70 2203337.48 780154.25 265250.15
PKD1 mean coverage (X) 331.14 89.20 80.60 13.60
% PKD1 target bases covered = 0X 1.98 0.35 3.70 0.39
% PKD1 target bases covered ≥ 1X 98.02 0.35 98.15 0.20
% PKD1 target bases covered ≥ 20X 95.54 1.98 86.69 2.59
% PKD1 target bases covered ≥ 50X 92.40 4.13 65.03 4.76
% PKD1 target bases covered ≥ 100X 84.78 6.84 52.01 1.65
PKD2 mean coverage (X) 480.73 87.98 174.22 28.72
% PKD2 target bases covered = 0X 0.36 0.11 0.90 0.20
% PKD2 target bases covered ≥ 1X 99.64 0.11 99.55 0.10
% PKD2 target bases covered ≥ 20X 99.19 0.20 98.75 0.31
% PKD2 target bases covered ≥ 50X 98.68 0.37 92.74 3.46
% PKD2 target bases covered ≥ 100X 97.10 2.22 67.51 8.70
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genes with highly homologous pseudogenes. In addition,
two previously known large deletions were correctly
detected. Concretely, patient 03-106-P6 presented PKD1
g.2154344-2186386del (Fig. 2A), and patient 11-571-P2
presented PKD2 g.88952828-89050618del (Fig. 2B). For
the unique patient with a previously known mutation not
identified by our NGS assay, 03-393-P3, manual
inspection of the sequence alignment files revealed that
the missing p.(Met1fs) was localized in a region of exon 1
of PKD1 for which no NGS reads were available due to
problems with the genomic capture.
We included in this study five control individuals with-
out personal or family history of ADPKD to determine
the clinical specificity of our assay. These controls had
been previously genotyped with a HumanOmni 2.5-8
BeadChip (Illumina, Inc.) and were also used to deter-
mine the analytic sensitivity of our assay to detect hetero-
zygous and homozygous SNVs. Genotype data were
available for a total of 80 and 269 sites within the targeted
regions of PKD1 and PKD2, respectively. Sensitivity was
of 100% both for PKD1 (20/20) and PKD2 (103/103).
Analytic specificity was 100% both for PKD1 (60/60) and
PKD2 (166/166) (Table S5). Of note, no spurious patho-
genic calls were detected in either the control individuals
or the validation cohort.
Identification of PKD1 and PKD2 mutations
in the discovery cohort
We detected pathogenic mutations in 10 out of 12
patients carrying a total of 11 different pathogenic muta-
tions (10 in PKD1 and one in PKD2), which lead to a
diagnostic rate of 83.3%. All variants were confirmed by
Sanger sequencing (Table 3). Interestingly, one patient
(12–444) harbored one definitively pathogenic mutation
in PKD2 and one highly likely pathogenic mutation in
Figure 1. Representation of the average depth of coverage of PKD1 (A) and PKD2 (B) in the validation cohort. Red lines and the numbers
underneath represent the exons of the genes. Green lines represent the regions tilled by capture baits.
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PKD1, presenting a more severe phenotype compared to
the rest of the family. For the two samples in which no
pathogenic variants were identified with our NGS assay,
the bioinformatics pipeline proposed a list of candidate
regions with low sequence coverage that were screened by
Sanger sequencing and the two causal mutations were
identified. Then, by manually inspecting the alignment
files of the NGS reads, we realized that we had lost
p.(Val2768Met) in patient 13-102 and p.(Arg4021fs) in
patient 07-335 because their locations were in poorly cov-
ered areas of PKD1 and the variant calling and filtering
algorithms had discarded them as potential false positives
calls. Noteworthy, no spurious pathogenic calls were
reported in any of the samples of the discovery cohort.
Discussion
It has been suggested that the impact that NGS technolo-
gies will have on clinical genetics during the upcoming
years will be comparable to the introduction of X-rays to
medicine many decades ago (Hennekam and Biesecker
2012). After the tremendous impact of NGS technologies
in the discovery of disease-causing genes during the last
4 years, we are witnessing the introduction of these tech-
nologies for diagnostic applications, with the aim of rap-
idly revolutionize the field of genetic diagnostics, making
it much more cost- and time-effective, advance accuracy,
and point to unsuspected yet treatable conditions. The
purpose of this study was to develop a cost-effective
Table 2. ADPKD mutations in PKD1 and PKD2 identified in the 36 samples of the validation cohort.
Sample Gene
Duplicated
region cDNA change Protein change PKDB # Patients Classification
Ref
counts
Variants
counts
03-106-P6 PKD1 Yes c.1-?_8161+?del p.(Met1fs) Absent 0 Definitely pathogenic – –
12-331-P1 PKD1 Yes c.566C>G p.(Ser189*) Present 1 Definitely pathogenic 188 62
12-382-P1 PKD1 Yes c.736_737del p.(Ser246fs) Absent 0 Definitely pathogenic 19 14
04-016-P6 PKD1 Yes c.1831C>T p.(Arg611Trp) Present 1 Likely pathogenic 25 13
12-235-P1 PKD1 Yes c.2329C>T p.(Gln777*) Absent 0 Definitely pathogenic 59 37
12-366-P1 PKD1 Yes c.2478delC p.(Ile827 fs) Absent 0 Definitely pathogenic 114 83
12-010-P1 PKD1 Yes c.4888C>T p.(Gln1630*) Present 1 Definitely pathogenic 136 114
02-010-P6 PKD1 Yes c.6583_6589del7 p.(Cys2195fs) Present 1 Definitely pathogenic 74 79
10-326-P3 PKD1 Yes c.6778_6780delATT p.(Ile2260del) Present 1 Highly likely Pathogenic 190 148
11-220-P2 PKD1 Yes c.6221delA p.(Asn2074fs) Absent 0 Definitely Pathogenic 123 113
11-247-P7 PKD1 Yes c.6384C>A p.(Asn2128Lys) Absent 0 Highly likely pathogenic 181 131
12-161-P1 PKD1 Yes c.6586C>T p.(Gln2196*) Present 1 Definitely pathogenic 86 50
11-517-P1 PKD1 Yes c.6736C>T p.(Gln2246*) Present 1 Definitely pathogenic 185 124
11-525-P2 PKD1 Yes c.6827T>C p.(Leu2276Pro) Absent 0 Highly likely pathogenic 280 245
10-388-P3 PKD1 Yes c.8161+1G>C p.(?) Absent 0 Definitely pathogenic 21 25
11-468-P1 PKD1 Yes c.8251C>T p.(Gln2751*) Absent 0 Definitely Pathogenic 92 92
12-363-P1 PKD1 Yes c.8285delT p.(Ile2762fs) Absent 0 Definitely Pathogenic 120 89
10-463-P3 PKD1 Yes c.8311G>A p.(Glu2771Lys) Present 18 Highly likely pathogenic 58 63
11-457-P2 PKD1 Yes c.8858A>G p.(Asn2953Ser) Absent 0 Highly likely pathogenic 236 191
11-287-P2 PKD1 Yes c.9240_9241delAT p.(Ala3082fs) Present 3 Definitely pathogenic 164 80
10-193-P3 PKD1 Yes c.9412G>A p.(Val3138Met) Present 2 Likely Pathogenic 208 188
11-595-P2 PKD1 Yes c.9455_9456insC p.(Arg3152fs) Absent 0 Definitely pathogenic 283 184
07-172-P5 PKD1 Yes c.9889G>A p.(Val3297Met) Absent 0 Likely pathogenic 130 114
09-403-P3 PKD1 Yes c.10170+25_+45del19 p.(Gln3390fs) Present 2 Highly likely pathogenic 96 26
10-182-P3 PKD1 – c.11017-10C>A p.(Arg3672fs) Present 7 Highly likely pathogenic 109 83
12-144-P1 PKD1 – c.10847C>A p.(Ser3616*) Absent 0 Definitely Pathogenic 224 177
10-353-P3 PKD1 – c.11359_11360del p.(Pro3788fs) Absent 0 Definitely pathogenic 292 203
11-256-P2 PKD1 – c.11471G>T p.(Gly3824Val) Absent 0 Likely pathogenic 85 63
11-168-P8 PKD1 – c.12004-2A>G p.(?) Absent 0 Definitely pathogenic 143 113
09-446-P3 PKD1 – c.12031C>T p.(Gln4011*) Present 4 Definitely pathogenic 106 85
11-133-P8 PKD2 – c.224delC p.(Pro75fs) Absent 0 Definitely pathogenic 41 25
11-008-P3 PKD2 – c.637C>T p.(Arg213*) Absent 0 Definitely pathogenic 198 172
11-170-P2 PKD2 – c.965G>A p.(Arg322Gln) Present 4 Highly likely pathogenic 396 330
12-149-P1 PKD2 – c.2050_2053del4 p.(Tyr684fs) Present 1 Definitely pathogenic 212 181
11-571-P2 PKD2 – c.709-?_2907+?del p.(Leu237_
Val968del)
Absent 0 Definitely pathogenic – –
09-393-P3 – – – – – – – –
#Patients in previous studies, NM_001009944.2 for PKD1 and NM_000297.2 for PKD2
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method for the molecular diagnostics of ADPKD applying
targeted NGS. First, we validated the assay in a cohort of
36 previously characterized ADPKD patients in which we
detected 35 out of 36 known mutations. Second, we ana-
lyzed a discovery cohort of uncharacterized ADPKD
patients and we reached a diagnostic rate of 83% (10 out
of 12 patients), allowing test reporting 5 days after receiv-
ing the DNA samples. Although the size of our cohort is
modest, these results are very encouraging since these
numbers represent a diagnostic rate comparable to data
obtained by Sanger sequencing (Audrezet et al. 2012;
Cornec-Le Gall et al. 2013) and NGS (Rossetti et al.
2012).
Recently, targeted sequencing by NGS has been used in
the identification of mutations in ADPKD. Rossetti et al.
(2012) did not apply a capture protocol for PKD1 and
PKD2 enrichment since they speculated that the dupli-
cated genomic regions of PKD1 would lead to concurrent
capture of the six PKD1 pseudogenes making very difficult
the identification of the ADPKD causal variants. Instead,
these authors used a strategy of pooling equimolar LR-
PCR amplicons and multiplexing barcoded libraries. Their
approach showed a high sensitivity, specificity and accu-
racy, but it is a very laborious task more amenable to
characterize large ADPKD populations than for routine
genetic diagnosis. Moreover, their approach did not allow
Figure 2. Detection of large deletions in the PKD1 and PKD2 genes by normalized depth of coverage analysis. Representation of the SVD-ZRPKM
values calculated by Conifer for the 36 samples and 5 controls of the validation cohort. Yellow peaks indicate the two large deletions identified in
this study. (A) Sample 03-106-P6 PKD10s deletion (g.2154344-2186386del). (B) Sample 11-571-P2 PKD2/ABCG20s deletion (g.88952828-
89050618del).
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detecting large genomic rearrangements. Here, we do not
only demonstrate that genome enrichment by in-solution
hybridization using an elaborated probe design is an accu-
rate strategy for mutation identification in the duplicated
regions and the rest of PKD1 and PKD2, but also that this
strategy is ready to substitute LR-PCR-based methods in
the routine genetic diagnostics of ADPKD to detect all
sorts of sequence variants, including SVs.
When we conceived this study, we assumed that it
would be extremely difficult to specifically capture the
genuine PKD1, that is, there would always be residual
enrichment of the six pseudogenes. Therefore, instead of
excluding this region from our assay we decided to
include unspecific probes to the duplicated region of
PKD1 in our capture library. In this regard, the mutation
calls are on average lower than the reference calls, most
likely due to the pseudogenes background (Tables 2, 3).
From our point of view, the critical point of the assay
was not the presence of sequencing reads coming from
both the genuine PKD1 and its pseudogenes. Instead, the
major challenge was to map the reads coming from dupli-
cated regions unambiguously to the genuine PKD1 or to
the six pseudogenes.
In order to minimize the impact of sequence reads
coming from the pseudogenes we allowed mapping to
the whole genome, instead of restricting the mapping
to the targeted region. Moreover, the length of the mil-
lions of overlapping sequencing reads produced in this
study (2 9 100 bp and 2 9 250 bp in the validation
and discovery cohorts, respectively) in combination with
the 300 bp insert sizes in the DNA libraries provided
enough sequence specificity for accurate mapping and
pseudogene discrimination, allowing us to unambigu-
ously map a large proportion of the sequencing reads
to PKD1 (Table 1).
Furthermore, we also assume that the alignment algo-
rithm is not 100% reliable and some reads coming from
the pseudogenes could have been erroneously aligned to
PKD1. In the worst scenario, the accumulation of these
misaligned reads could lead to spurious variant calls but,
as we have observed, none of these potential false positive
variant calls passed the stringent filters of our variant pri-
oritization pipeline in any of the patients of the validation
and discovery cohorts neither in the five control samples.
The low sequencing coverage obtained for exons 1 and
42 of PKD1 and exon 1 of PKD2, likely due to a high GC
content, is the main limitation of this study as all variants
that were missed were located in these poorly covered
regions highlighting the importance of achieving sufficient
depth of coverage for the optimal performance of the
assay. However, we think that this can be fixed by rebal-
ancing and adding new and replicate probes hybridizing
with these poorly covered regions in the capture design.
In the discovery cohort, the low average depth of cover-
age yielded by the MiSeq (Illumina, Inc.) in some samples
was the cause of the lower mutation detection rate of the
assay. However, we plan in the future to produce an opti-
mized capture design including only PKD1/PKD2 and a
few cystic genes that would help in the differential diag-
nosis, such as HNF1B (17p12; OMIM ID: 189907) and
PKHD1 (6p12.3-p12.2; OMIM ID: 606702). This would
significantly reduce the total captured DNA per sample,
allowing multiplexing more samples per MiSeq (Illumina,
Inc.) run, and to achieve higher depths of coverage (com-
parable to those obtained for the validation cohort) that
will allow more confident variant calling.
We estimate that with our NGS-based assay a 60% of
cost savings per sample could be achieved, and the whole
diagnostics process could be a minimum of five times fas-
ter than with the conventional techniques currently used
Table 3. ADPKD mutations in PKD1 and PKD2 identified in the 12 samples of the discovery cohort.
Sample Gene
Duplicated
region cDNA change Protein change PKDB # Patients Classification Ref counts Variants counts
06-056 PKD1 Yes c.348_352delTTTAA p.(Asn116fs) Present 1 Definitely pathogenic 28 20
06-122 PKD1 Yes c.7204C>T p.(Arg2402*) Present 2 Definitely pathogenic 24 12
07-032 PKD1 Yes c.8421_8422insC p.(Ile2808fs) Absent 0 Definitely pathogenic 22 18
11-444 PKD1 Yes c.8041C>T p.(Arg2681Cys) Absent 0 Highly likely pathogenic 38 20
12-444 PKD2 – c.1532_1533insAT p.(Asp511fs) Absent 0 Definitely pathogenic 156 70
PKD1 – c.10921C>T p.(Arg3642Cys) Absent 0 Highly likely pathogenic 40 52
12-505 PKD1 Yes c.50174_5015delAG p.(Arg1672fs) Present 28 Definitely pathogenic 118 88
13-199 PKD1 Yes c.7039delC p.(Arg2347fs) Absent 0 Definitely pathogenic 34 32
12-628 PKD1 Yes c.2180T>C p.(Leu727Pro) Absent 0 Highly likely pathogenic 20 8
08-258 PKD1 Yes c.7925C>T p.(Arg2639*) Present 5 Definitely pathogenic 28 14
10-484 PKD1 – c.12010C>T p.(Gln4004*) Present 4 Definitely pathogenic 26 38
13-102 – – – – – – – – –
07-335 – – – – – – – – –
# patients in previous studies, NM_001009944.2 for PKD1 and NM_000297.2 for PKD2.
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for the genetic diagnostics of ADPKD. In addition, our
strategy offers a complete definition of the captured genes,
without the need for stepwise testing anymore and having
to choose which gene to sequence first, and is capable to
detect large genomic rearrangements and deep intronic
variants. In the discovery cohort, the complete process of
library preparation, genomic enrichment, NGS using a
MiSeq (Illumina, Inc.), and bioinformatics analysis was
completed in 5 days after reception of the DNA samples.
In conclusion, we illustrate here the first successful
study using in-solution hybridization enrichment coupled
to NGS to detect ADPKD pathogenic mutations, both in
the duplicated regions of PKD1 and the rest of PKD1 and
PKD2 genes. Our approach is cost- and time-effective,
and meets the sensitivity and specificity criteria required
for genetic diagnostics, providing NGS experimental and
bioinformatics approaches ready to substitute classic
molecular tools in routine genetic diagnostics of ADPKD.
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